{"ticker": {"uuid": "562bd783-95eb-426a-b811-736b87be555b", "symbol": "AARD", "name": "Aardvark Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxOX3NwSU42TE5jaUM1cVFnU0lVQmtTZ1FWLUhaU3hvbzRlbG5tdmxUSHMzMkpSbC1JU1FtVnRjLXpQRFNZaTBRMU1DTXh0VEJ3enJQd0g1eEVxU1oyaUk3TkVQYURLdFV1cm1RejBqODJEcm9JMVpEd2RfOVZGWHNxaGJNMEsxZjlVdFlBdG8xRlljYkR4Nk1vamYyWU1BM1BDdWEteWZQb1MwdVFSLXlEM1Z3MFdZRnQ4QVB0QXhaM2VCRko2N09DMlFod3hteExaR2JwTnZJVElheVNyWlVkbGF6Y0MxSEJlOTJYeGZKamtmTzkxNHRnYXZyQjBtWWJxOTE4enJQMDVIejgzRG5pSmJsQUtFTDJ3R1BWWTl3eXVURGRaQno5emlnSVF0SWxCN3JXMWdYcWpXdWszbHJNZGY0VHRsRUY1cHpZYklyZ1Yxdw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T15:29:13+00:00", "published_display": "14 Jul 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxOc0s0U01kTDZiWkFyY0F4VjVpb3RZRFNlLTN5eFF0RjY1LTU1ZlNkb2N4YzFORkRMbmJLdEhMaUVkek1Lc3BqSzBJSENqdlE4ZW9adHpZVWhWZ2NNbnhCU2taNi1HZWVST2FJVEdhZGVOYUM4Yzg4dTdIYS15TWt0Uzc0TnJCWkxCeVdPRGp4RVZsb2xKMUg5Z29DRmVNMzdmRTlYcjBRU2Z5T1BCaU9hVkJpZFJ0ZFQxaVdobjlOOWw0ZDNCNGduTHNCUU1qNThlNlItVmEycVQySnJSbTRGMXVrazN2dEcweU1CdllTd1NxV3lKMXc2Y1JOaw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-11T11:45:56+00:00", "published_display": "11 Jul 2026 11:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement", "summary": "Aardvark Therapeutics, Inc. is holding a virtual annual stockholders' meeting on August 14, 2026, to vote on three proposals including the election of two Class I directors, ratification of BDO USA, P.C. as auditor, and a significant repricing of underwater employee stock options", "url": "https://www.stocktitan.net/sec-filings/AARD/def-14a-aardvark-therapeutics-inc-definitive-proxy-statement-36c3a98b2c1d.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:56", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Cantor Global Healthcare Conference 2025 Summary", "summary": "This summary of Aardvark Therapeutics' (AARD) Cantor Global Healthcare Conference 2025 presentation details their focus on gut-restricted, oral small molecule drugs for hunger and appetite, particularly for Prader-Willi syndrome and obesity. The company highlighted promising prec", "url": "https://quartr.com/events/aardvark-therapeutics-inc-aard-cantor-global-healthcare-conference-2025_F6vEiG5T", "source_name": "Quartr", "published_at": "2026-07-08T11:40:57", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (NASDAQ: AARD) asks shareholders to reprice 2.8M options", "summary": "Aardvark Therapeutics is seeking shareholder approval to reprice approximately 2.8 million outstanding stock options, representing about 13% of its issued share capital. This move aims to retain and motivate employees whose options are currently \"underwater\" due to a significant ", "url": "https://www.stocktitan.net/sec-filings/AARD/pre-14a-aardvark-therapeutics-inc-preliminary-proxy-statement-d7c7ec7ef9ed.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:54", "published_display": "29 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Dynamic Index", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from several Russell indices, including the Russell 2000 Dynamic Index, Russell 3000E Index, Russell Small Cap Completeness Index, Russell 2500 Index, and Russell 3000 Index. This follows recent news from May where the ", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-2000-dynamic-index-ce7f5fdfdc8dfe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:33:00", "published_display": "29 Jun 2026 17:33", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 3000E Index", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS: AARD) has been removed from the Russell 3000E Index, among several other Russell indices, on June 29, 2026. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapies for metabolic diseases, with its lead produc", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-3000e-index-ce7f5fdfda88f227", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T14:02:00", "published_display": "29 Jun 2026 14:02", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aardvark Therapeutics, Inc. \u2013 NASDAQ:AARD", "summary": "The article focuses on the \"Price to earnings forward\" metric for Aardvark Therapeutics, Inc. (NASDAQ: AARD). It briefly presents this financial data point within the context of the company's profile on TradingView. The page primarily shows navigation and disclaimer information, ", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T10:39:22", "published_display": "29 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS", "summary": "Hagens Berman has initiated an investigation into Aardvark Therapeutics (NASDAQ: AARD) after its stock price dropped 56% following the company's announcement to pause its Phase 3 HERO trial for ARD-101 due to serious safety concerns, specifically \"reversible cardiac observations.", "url": "https://www.prnewswire.com/news-releases/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-drug-candidate-hbss-302810290.html", "source_name": "PR Newswire", "published_at": "2026-06-29T10:39:22", "published_display": "29 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Value Benchmark", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from the Russell 3000 Value Benchmark. This decision follows a series of recent events, including a significant drop in share price due to an FDA clinical hold on its lead drug candidate, ARD-101, and subsequent analyst", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-3000-value-benchmark-ce7f5fdeda8ff621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:40:17", "published_display": "29 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Stock Slumps 54% Pre-Market \u2013 Here\u2019s Why Analysts Are Not \u2018Comfortable\u2019 With The Suspension Of A Key Phase 3 Trial", "summary": "Aardvark Therapeutics (AARD) shares plunged 54% pre-market after the company voluntarily paused its HERO Phase 3 trial due to reversible cardiac effects found in a healthy volunteer. This unexpected development led to multiple brokerage downgrades, with analysts expressing signif", "url": "https://stocktwits.com/news-articles/markets/equity/aard-stock-slumps-pre-market-analysts-bearish-suspension-phase-3-trial/cZd3BeGRI2P", "source_name": "Stocktwits", "published_at": "2026-06-29T03:41:03", "published_display": "29 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 2500 Value Benchmark", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from the Russell 2500 Value Benchmark, according to an announcement published on June 28, 2026, by S&P Capital IQ. This follows its removal from several other Russell indices on June 29, 2026, including the Russell 2000", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-2500-value-benchmark-ce7f5fded880ff21", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:13:00", "published_display": "28 Jun 2026 21:13", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc. Actuals & Estimates (BOATS:AARD)", "summary": "This article provides an overview of Aardvark Therapeutics, Inc. (BOATS:AARD) stock, including financial actuals, analyst estimates, historical price data, and upcoming earnings information. It highlights key financial metrics, earnings surprises, revenue details, and confirms th", "url": "https://www.tradingview.com/symbols/BOATS-AARD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T07:10:37", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc. Actuals & Estimates (NASDAQ:AARD)", "summary": "This article provides an overview of Aardvark Therapeutics, Inc. (NASDAQ: AARD) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial estimates, past earnings reports, upcoming earnings da", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T16:10:08", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Company Profile & Introduction", "summary": "This article provides a company profile and introduction to Aardvark Therapeutics.", "url": "https://www.moomoo.com/stock/AARD-US/company?chain_id=Name1K9-3FXPhg.1l0a440&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2F688050-SH%2Fforecast%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T08:10:09", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Aardvark Therapeutics, Inc. (AARD) stock, including current price, analyst ratings, price targets, and historical performance. It details financial metrics such as earnings per share and revenue, upcoming earnings dates, market capitalization,", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:37", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aardvark Therapeutics, Inc. \u2013 NASDAQ:AARD", "summary": "This article provides financial data for Aardvark Therapeutics, Inc. (NASDAQ: AARD), specifically focusing on its forward price-to-sales ratio. The content is sourced from TradingView, which offers various financial tools and market data services. It includes an overview of the c", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:09", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai", "summary": "The Nasdaq Biotechnology Index experienced a rise of over 1.52%. Absci, Silence Therapeutics, Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies were among the constituents that saw significant gains. Conversely, Abivax ADR, Quan", "url": "https://www.bitget.com/amp/news/detail/12560605476169", "source_name": "Bitget", "published_at": "2026-06-24T21:40:21", "published_display": "24 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Leads The Charge With 2 Other Noteworthy Penny Stocks", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides historical dividend and stock split information for Aardvark Therapeutics Inc (AARD). It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. Financial data shows AARD with a market cap", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aard/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:28", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Inc (AARD) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Aardvark Therapeutics Inc (AARD), including its current stock price and market capitalization. It lists key institutional shareholders and their shareholdings, noting changes in their positions. The informati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aard/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:32", "published_display": "17 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Aardvark Therapeutics Inc (AARD), detailing its current stock price, market capitalization, and various valuation metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these metrics have not yet been disclosed by the ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aard/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:32", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD)", "summary": "Aardvark Therapeutics (NASDAQ: AARD) has approved cash retention bonuses for two senior executives: CFO and COO Nelson Sun, and CMO Manasi Jaiman, M.D., M.P.H. Sun is eligible for a total of $346,500 and Jaiman for $357,000, with both packages comprising a guaranteed annual bonus", "url": "https://www.stocktitan.net/sec-filings/AARD/8-k-aardvark-therapeutics-inc-reports-material-event-f3168d97e4e2.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:38:58", "published_display": "12 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD", "summary": "Pomerantz LLP is investigating Aardvark Therapeutics, Inc. (AARD) on behalf of investors for potential securities fraud and unlawful business practices. This investigation follows a significant drop in Aardvark's stock price after the company voluntarily paused its Phase 3 HERO t", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-aardvark-therapeutics-inc---aard-302796267.html", "source_name": "PR Newswire", "published_at": "2026-06-11T14:10:08", "published_display": "11 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59", "summary": "Insiders of Aardvark Therapeutics, Inc. who purchased US$450.3k worth of stock at an average price of US$9.79 over the last year have seen their investment decline to US$165.1k due to a recent 10% stock decrease to US$3.59. Despite the losses, insiders, including CEO Tien-Li Lee,", "url": "https://www.sahmcapital.com/news/content/aardvark-therapeutics-insiders-lose-out-as-stock-sinks-to-us359-2026-06-09", "source_name": "Sahm", "published_at": "2026-06-09T14:09:21", "published_display": "09 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid", "summary": "Hagens Berman has initiated an investigation into Aardvark Therapeutics (AARD) after the company's shares dropped 56% following the pause of its Phase 3 HERO trial for ARD-101. The pause was due to \"reversible cardiac observations,\" raising concerns about the accuracy of Aardvark", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305624/32716/en/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-drug-candidate-hagens-berman.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T02:09:54", "published_display": "03 Jun 2026 02:09", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Several Insiders Invested In Aardvark Therapeutics Flagging Positive News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNS005S3pBakVnU2FiZTNld29pWEI4WUNndTZQMll5OExrRlUyTXlGWUxFVVUteV9ZNW0zZnpjaHBRbmVLUGJkXy1aRlNQcnNzTmt6WUgzVlE0azRmdEdiSXBuZ3ZSWV9OOUJ6VnM1c2ZWamplUURfeDJjTVJpNmtsRmM5aWZ1UEhGcGZtYlpKanZaVUE2NmFWbFh1WDVnQ25GbnZZMXVyWHN1dnNJRWliMGRR?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Downgrades Aardvark Therapeutics to Neutral From Buy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/btig-downgrades-aardvark-therapeutics-neutral-122928437.html", "source_name": "MT Newswires", "published_at": "2026-05-15T12:29:28+00:00", "published_display": "15 May 2026 12:29", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA hold puts Aardvark Prader-Willi drug in limbo", "summary": "", "url": "https://finance.yahoo.com/m/4ae94c68-6536-3188-8a3e-62a42055b0af/fda-hold-puts-aardvark.html", "source_name": "BioPharma Dive", "published_at": "2026-05-15T11:58:00+00:00", "published_display": "15 May 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-adjusts-aardvark-therapeutics-114451883.html", "source_name": "MT Newswires", "published_at": "2026-05-15T11:44:51+00:00", "published_display": "15 May 2026 11:44", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Downgrades Aardvark Therapeutics to Underweight From Equalweight, Cuts Price Target to $3 From $7", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-downgrades-aardvark-therapeutics-102850381.html", "source_name": "MT Newswires", "published_at": "2026-05-15T10:28:50+00:00", "published_display": "15 May 2026 10:28", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG downgrades Aardvark Therapeutics stock rating on FDA hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOaVpOM0ptZVEtSzNrRFFMSDdTX2dVdFJOLTYxRTNId05uT05xSDY4YWxXcllWb2tzR1BoQnhtS3M3aFBpMENmUzNCbHo0SlRqY3VZMHNhLVF6cjNrMWNHa21OZ2hlWktvbkt4TmVLekdWRC1tR0kwTmhONFdTdkJaUU9TLUhaMmo2eHRYYm1jcWZFdGpNMHd5bGpyblAtMURMWmZRVDNyZDBkMW9rYV9FWFpncFFhUnc1ZEFXMWxPVQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Stock Crashes 34% \u2013 Here\u2019s Why This Analyst Finds It \u2018Hard To Lean Into\u2019 Aardvark At This Stage", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxObmY4M0JiU19lMDhiN3RtNDAzSFhsRDQ2UDYwMUt5WDZqSDJzOW4xeF9lS2h6WXlUZ0F0b0k4Mkd0a29XSzJjeTRXeElDZDVrYkJoMmE3WkF6N0otcjV0MTNKakhmMlpZUV9XWkhENnJ0WHp5UHNGTkNnX290eWFzaTlXQ1RuSy0wOHl5VzFwUkdRZDRvdDRwemhYSGFYQ2hETkpqNVUxdVJRVk1uOWxyeURR?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $19.3, Implies 187% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPZVVWMktTVFdrVE1nams1TUdkQ1J0NWVhazdVYXBVeVJ6ZjBEUHJ2N20yMm1LeUJGTmtDbTh1NVl5WU9NT3FySUpWZG1feGRVVHFaajJzWWxqM3FvaEowTEM2WWVZcUJFTERuUkE0WXBTSkQ5b2o3TGFHbzdoS2lrU241bTd1d0otbDJjTmNoRGh5dEk1QlpJSkJlTFI4NlJxR1VhWlFCSzFPUXRycm50T3duNTdJdjE1NERGSV9LT3k3MkNaa1M3Z1NyLVlZTTFZdHllOW11Tms3ZlJNRUw0?oc=5", "source_name": "TradingView", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNa1JtZ09uOExjWm03czFJcEM1eFpjWC1YcGVqVGdyX3hlbXNWckg0ejNlWUNyWHh1T3BGVTh6UGVmSWk1UktNVWRhWmVNQWFCejN0WjFiUGdYaEFkRFNiaUNyV0hiRnBqRGZvMGFKODJMU3hDZm9iNjcxakE1SndnT0FtZ2RDLTM4M2NxZm1nR3pGTVVzbGtQSGx4V0g5VzFhNDIwZ2Q1RmxtYVFYMUhNRVJYS2l4SHJfRmkwZ1RUbVVCZXFGMms5NVRNN2YzdEE1cGNNVENnSzN1T3kwTXUteng0VTZBQ2NZSkFlVHhRSEQ5R2s?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AARD Stock Price and Chart \u2014 NASDAQ:AARD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ZdmNseUxOWjZ1NnFkSUxwbWlkODByaVFuZXMzYk1zSk1sZzdzN0pYUk1HYjdWcXA5R2tQQ08zRkd0QlVWNmQtX1VLM29qbGpnOFZqZG1VQVJRcDB0?oc=5", "source_name": "TradingView", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$AARD stock is down 14% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWnItRXJBV3BieV9IVHJWbTBCcmJjS3g2bjJFSTl4V0FZTEpyQnF3VG91XzZEZTlzNUhvSURTR2paZ3NKVVo3ei1JMmtPRW5ZUUtWXzF1MFUwQTRzNkU4VklHS3RSYmx5ODlNMEYybklPVXVDa05OMU1fNHVZRlJud2luTGUteFBGVVI4ZUlXLVd2Vm5SX2ZleFlibjVKdkd5ZjlN?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOVDRQeFhKNlVwUVRVNExGbzROdTg1NmZJbUVPaWZrSzN4endNNjVPNmVxYl9kckluaGY2eFBBSWFUb2FDZTYxVXZsMTRJTHRpMlpnZUN0RXppRTZYTVZKOGlKcVZ0Yk9pdUZRS3NJRkY4SnU4WmVHNlNwb2tRMjJnZDgtd3Z3YUE?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQSXhZVnJGQ2tSd0VLRUh5bTJfV25LMjJYSGtnNHZnOFA3bUNHQ0VWcE9oRzJfdnFWV2RkOTVoRFgwMC0weEdXcTFGeDZTcDFWclQxRWFpdGJraTAzbkg1RzMtZVdvZmh5MEwtcEVJLXY5LTZOWkhZazIyT3RqNW1YLURsSGdzVHh6dDgxZDFKbi1TdHZFZEtZSnNvXzhyWmxmeERSTmxVRVZmR3lDLTVKMUd6YjZ1dlBJOHdUckdJbnBUMDFwTGs5bGVLQ2NiYjQwbThQbHRXTlk3SG1kbC1pQXVoMDdUdWd3aHJj0gHwAUFVX3lxTFBYR2FncXlCNXkwWTItWHZudTAyZ0tBX1UyRkpEMG56WWJaT1ZObE5XajFPVkNjVXJkSmRzZDFDTnJOWF8wTWUtY3FYc2YtRHFpX09kMWh2SV9oVU5rbUdnZGNSMUlOUkt3ZkRYeVd5UmFYamlrUGNSRnhKSjFKRnJQenJMRTJXYUo5cWNSSFdUZzJqTkxGekZ4Z3oyMXNXQnZqWW5jQmRCcGJvdEh4NkdONGFjRUVZRkxWN0N1WGxSbERaQXc0RGZHa0pVcnFzUUhXUFlHb1NPRUMzXy1nUDZFcmJHcXZGT25kT0lNVlVncA?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPWmdETGg5S2JNZFhWMDltaDBnR1lfaTVmdVZKYzVkUzdVaEhMMzdNQXExR3pfdmM4TmNRQmx6akp5aFI2RlpYN1NfcV9fZ3J1Qm5NZzdZdHc5ekpSSE00cXF0ZEJrZmtUc0U0cjZHQjhPQVBadVVEOVc5QkNHbHU5VGpMTDBPLTMxQ0hQbDdFX1BjcUJRbUEtVWJuNkN2RGc1RXpPNGNoQ2UyUHc4TzdRd2dIY25uektjVUJWRWQtVGpWdFhTNjRjZEdGWk1jMm5lMnFJNWxsOEpOM2pTS1lCUFFQR1hZRnBlOHJZMlhKejFMSkRQdWl6cXMwYw?oc=5", "source_name": "Benzinga", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (NASDAQ: AARD) posts new January 2026 presentation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNlMyTFQyLXFXQ2N0WjlOSndLa1lPVzd5cEN1c0Q2LURpXzFycGpHNm9pTDAtMWdGUmxSM0F0enJBMHNzbTNVY1hJZnRERjh5eTJUbURPSHBHdXdYQUxyanRNSFlsb2VtY0psNjVhUHQ3WGg3NlYzZFprOS1RNnFYLUttX3BHTmUzZUlzY0FybjJSNHVOWkNHT1NrRmp6Yk9QTW5aRm5EWmVlVWVfcmxEaXBzSXk?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxOX3NwSU42TE5jaUM1cVFnU0lVQmtTZ1FWLUhaU3hvbzRlbG5tdmxUSHMzMkpSbC1JU1FtVnRjLXpQRFNZaTBRMU1DTXh0VEJ3enJQd0g1eEVxU1oyaUk3TkVQYURLdFV1cm1RejBqODJEcm9JMVpEd2RfOVZGWHNxaGJNMEsxZjlVdFlBdG8xRlljYkR4Nk1vamYyWU1BM1BDdWEteWZQb1MwdVFSLXlEM1Z3MFdZRnQ4QVB0QXhaM2VCRko2N09DMlFod3hteExaR2JwTnZJVElheVNyWlVkbGF6Y0MxSEJlOTJYeGZKamtmTzkxNHRnYXZyQjBtWWJxOTE4enJQMDVIejgzRG5pSmJsQUtFTDJ3R1BWWTl3eXVURGRaQno5emlnSVF0SWxCN3JXMWdYcWpXdWszbHJNZGY0VHRsRUY1cHpZYklyZ1Yxdw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T15:29:13+00:00", "published_display": "14 Jul 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxOc0s0U01kTDZiWkFyY0F4VjVpb3RZRFNlLTN5eFF0RjY1LTU1ZlNkb2N4YzFORkRMbmJLdEhMaUVkek1Lc3BqSzBJSENqdlE4ZW9adHpZVWhWZ2NNbnhCU2taNi1HZWVST2FJVEdhZGVOYUM4Yzg4dTdIYS15TWt0Uzc0TnJCWkxCeVdPRGp4RVZsb2xKMUg5Z29DRmVNMzdmRTlYcjBRU2Z5T1BCaU9hVkJpZFJ0ZFQxaVdobjlOOWw0ZDNCNGduTHNCUU1qNThlNlItVmEycVQySnJSbTRGMXVrazN2dEcweU1CdllTd1NxV3lKMXc2Y1JOaw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-11T11:45:56+00:00", "published_display": "11 Jul 2026 11:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement", "summary": "Aardvark Therapeutics, Inc. is holding a virtual annual stockholders' meeting on August 14, 2026, to vote on three proposals including the election of two Class I directors, ratification of BDO USA, P.C. as auditor, and a significant repricing of underwater employee stock options", "url": "https://www.stocktitan.net/sec-filings/AARD/def-14a-aardvark-therapeutics-inc-definitive-proxy-statement-36c3a98b2c1d.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:56", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Cantor Global Healthcare Conference 2025 Summary", "summary": "This summary of Aardvark Therapeutics' (AARD) Cantor Global Healthcare Conference 2025 presentation details their focus on gut-restricted, oral small molecule drugs for hunger and appetite, particularly for Prader-Willi syndrome and obesity. The company highlighted promising prec", "url": "https://quartr.com/events/aardvark-therapeutics-inc-aard-cantor-global-healthcare-conference-2025_F6vEiG5T", "source_name": "Quartr", "published_at": "2026-07-08T11:40:57", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (NASDAQ: AARD) asks shareholders to reprice 2.8M options", "summary": "Aardvark Therapeutics is seeking shareholder approval to reprice approximately 2.8 million outstanding stock options, representing about 13% of its issued share capital. This move aims to retain and motivate employees whose options are currently \"underwater\" due to a significant ", "url": "https://www.stocktitan.net/sec-filings/AARD/pre-14a-aardvark-therapeutics-inc-preliminary-proxy-statement-d7c7ec7ef9ed.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:54", "published_display": "29 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Dynamic Index", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from several Russell indices, including the Russell 2000 Dynamic Index, Russell 3000E Index, Russell Small Cap Completeness Index, Russell 2500 Index, and Russell 3000 Index. This follows recent news from May where the ", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-2000-dynamic-index-ce7f5fdfdc8dfe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:33:00", "published_display": "29 Jun 2026 17:33", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 3000E Index", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS: AARD) has been removed from the Russell 3000E Index, among several other Russell indices, on June 29, 2026. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapies for metabolic diseases, with its lead produc", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-3000e-index-ce7f5fdfda88f227", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T14:02:00", "published_display": "29 Jun 2026 14:02", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aardvark Therapeutics, Inc. \u2013 NASDAQ:AARD", "summary": "The article focuses on the \"Price to earnings forward\" metric for Aardvark Therapeutics, Inc. (NASDAQ: AARD). It briefly presents this financial data point within the context of the company's profile on TradingView. The page primarily shows navigation and disclaimer information, ", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T10:39:22", "published_display": "29 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS", "summary": "Hagens Berman has initiated an investigation into Aardvark Therapeutics (NASDAQ: AARD) after its stock price dropped 56% following the company's announcement to pause its Phase 3 HERO trial for ARD-101 due to serious safety concerns, specifically \"reversible cardiac observations.", "url": "https://www.prnewswire.com/news-releases/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-drug-candidate-hbss-302810290.html", "source_name": "PR Newswire", "published_at": "2026-06-29T10:39:22", "published_display": "29 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Value Benchmark", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from the Russell 3000 Value Benchmark. This decision follows a series of recent events, including a significant drop in share price due to an FDA clinical hold on its lead drug candidate, ARD-101, and subsequent analyst", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-3000-value-benchmark-ce7f5fdeda8ff621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:40:17", "published_display": "29 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Stock Slumps 54% Pre-Market \u2013 Here\u2019s Why Analysts Are Not \u2018Comfortable\u2019 With The Suspension Of A Key Phase 3 Trial", "summary": "Aardvark Therapeutics (AARD) shares plunged 54% pre-market after the company voluntarily paused its HERO Phase 3 trial due to reversible cardiac effects found in a healthy volunteer. This unexpected development led to multiple brokerage downgrades, with analysts expressing signif", "url": "https://stocktwits.com/news-articles/markets/equity/aard-stock-slumps-pre-market-analysts-bearish-suspension-phase-3-trial/cZd3BeGRI2P", "source_name": "Stocktwits", "published_at": "2026-06-29T03:41:03", "published_display": "29 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 2500 Value Benchmark", "summary": "Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from the Russell 2500 Value Benchmark, according to an announcement published on June 28, 2026, by S&P Capital IQ. This follows its removal from several other Russell indices on June 29, 2026, including the Russell 2000", "url": "https://www.marketscreener.com/news/aardvark-therapeutics-inc-nasdaqgs-aard-dropped-from-russell-2500-value-benchmark-ce7f5fded880ff21", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:13:00", "published_display": "28 Jun 2026 21:13", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc. Actuals & Estimates (BOATS:AARD)", "summary": "This article provides an overview of Aardvark Therapeutics, Inc. (BOATS:AARD) stock, including financial actuals, analyst estimates, historical price data, and upcoming earnings information. It highlights key financial metrics, earnings surprises, revenue details, and confirms th", "url": "https://www.tradingview.com/symbols/BOATS-AARD/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T07:10:37", "published_display": "27 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc. Actuals & Estimates (NASDAQ:AARD)", "summary": "This article provides an overview of Aardvark Therapeutics, Inc. (NASDAQ: AARD) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial estimates, past earnings reports, upcoming earnings da", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T16:10:08", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Company Profile & Introduction", "summary": "This article provides a company profile and introduction to Aardvark Therapeutics.", "url": "https://www.moomoo.com/stock/AARD-US/company?chain_id=Name1K9-3FXPhg.1l0a440&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2F688050-SH%2Fforecast%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T08:10:09", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Aardvark Therapeutics, Inc. (AARD) stock, including current price, analyst ratings, price targets, and historical performance. It details financial metrics such as earnings per share and revenue, upcoming earnings dates, market capitalization,", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:37", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aardvark Therapeutics, Inc. \u2013 NASDAQ:AARD", "summary": "This article provides financial data for Aardvark Therapeutics, Inc. (NASDAQ: AARD), specifically focusing on its forward price-to-sales ratio. The content is sourced from TradingView, which offers various financial tools and market data services. It includes an overview of the c", "url": "https://www.tradingview.com/symbols/NASDAQ-AARD/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:10:09", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai", "summary": "The Nasdaq Biotechnology Index experienced a rise of over 1.52%. Absci, Silence Therapeutics, Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies were among the constituents that saw significant gains. Conversely, Abivax ADR, Quan", "url": "https://www.bitget.com/amp/news/detail/12560605476169", "source_name": "Bitget", "published_at": "2026-06-24T21:40:21", "published_display": "24 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Leads The Charge With 2 Other Noteworthy Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPMWJuTG8zWW8tOV9uUEt1UTlhMTFJaE9pWGFVVzd6SEdpNVpSQklRQjQ1dmZldmdYUE1wUWxSWU82WVJSLWFPZVd1UUN6T18yVzl6cC1DdHd3V0JYeHJMM0g5clUycU96UGtuNWhZcS1zeXFiR0x0TG54eU1RS3p6NVphMHppZXY1cldDWFRxU2hmS21ZZzR1NkMyRnFSemJOWk9Tb29zemlMZHhYTFJjaEo2VWlaUFJqck1USEY2cUl3UWZ2REI4OXdORUZRUUd6cWxkbzcwNVFMbmFLRG12eS1oa0JmeXZPQjFF0gHwAUFVX3lxTE1WaVFLVHJ6V21JbUQtYV9NRkpHSmFlYVp4TzQwdmprX2UyZnRQTmRhcEdtWHFOQktkelh1Y3dGSlNKSU5Ub081ZkhQOFpPNW9fYlRlRGN1bGRPS1lRa1dlX3ZZdmJMU0ZiZWxuekxHaEVyc0luQkl2UmhEVkQyVTFZVVhBUk53Nm9MVGF2N1RhcWtIb2RDY0h4TTFVaEphMkVpMkR2Ui1RTEtBQnRJRWVOTDVuVGdrU0R1S0xoWHA2ajdiUXNzeGJqSXlJMTBqWmRJVktDWHh4SVJ1d1NtNTh4XzN0ZG90ZHV3dnQteFZndQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides historical dividend and stock split information for Aardvark Therapeutics Inc (AARD). It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. Financial data shows AARD with a market cap", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aard/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:28", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Inc (AARD) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Aardvark Therapeutics Inc (AARD), including its current stock price and market capitalization. It lists key institutional shareholders and their shareholdings, noting changes in their positions. The informati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aard/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:32", "published_display": "17 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Aardvark Therapeutics Inc (AARD), detailing its current stock price, market capitalization, and various valuation metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these metrics have not yet been disclosed by the ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aard/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:32", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD)", "summary": "Aardvark Therapeutics (NASDAQ: AARD) has approved cash retention bonuses for two senior executives: CFO and COO Nelson Sun, and CMO Manasi Jaiman, M.D., M.P.H. Sun is eligible for a total of $346,500 and Jaiman for $357,000, with both packages comprising a guaranteed annual bonus", "url": "https://www.stocktitan.net/sec-filings/AARD/8-k-aardvark-therapeutics-inc-reports-material-event-f3168d97e4e2.html", "source_name": "Stock Titan", "published_at": "2026-06-12T19:38:58", "published_display": "12 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD", "summary": "Pomerantz LLP is investigating Aardvark Therapeutics, Inc. (AARD) on behalf of investors for potential securities fraud and unlawful business practices. This investigation follows a significant drop in Aardvark's stock price after the company voluntarily paused its Phase 3 HERO t", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-aardvark-therapeutics-inc---aard-302796267.html", "source_name": "PR Newswire", "published_at": "2026-06-11T14:10:08", "published_display": "11 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59", "summary": "Insiders of Aardvark Therapeutics, Inc. who purchased US$450.3k worth of stock at an average price of US$9.79 over the last year have seen their investment decline to US$165.1k due to a recent 10% stock decrease to US$3.59. Despite the losses, insiders, including CEO Tien-Li Lee,", "url": "https://www.sahmcapital.com/news/content/aardvark-therapeutics-insiders-lose-out-as-stock-sinks-to-us359-2026-06-09", "source_name": "Sahm", "published_at": "2026-06-09T14:09:21", "published_display": "09 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid", "summary": "Hagens Berman has initiated an investigation into Aardvark Therapeutics (AARD) after the company's shares dropped 56% following the pause of its Phase 3 HERO trial for ARD-101. The pause was due to \"reversible cardiac observations,\" raising concerns about the accuracy of Aardvark", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305624/32716/en/aardvark-therapeutics-aard-faces-investor-scrutiny-amid-56-drop-on-clinical-pause-for-lead-drug-candidate-hagens-berman.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T02:09:54", "published_display": "03 Jun 2026 02:09", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Several Insiders Invested In Aardvark Therapeutics Flagging Positive News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNS005S3pBakVnU2FiZTNld29pWEI4WUNndTZQMll5OExrRlUyTXlGWUxFVVUteV9ZNW0zZnpjaHBRbmVLUGJkXy1aRlNQcnNzTmt6WUgzVlE0azRmdEdiSXBuZ3ZSWV9OOUJ6VnM1c2ZWamplUURfeDJjTVJpNmtsRmM5aWZ1UEhGcGZtYlpKanZaVUE2NmFWbFh1WDVnQ25GbnZZMXVyWHN1dnNJRWliMGRR?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Downgrades Aardvark Therapeutics to Neutral From Buy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/btig-downgrades-aardvark-therapeutics-neutral-122928437.html", "source_name": "MT Newswires", "published_at": "2026-05-15T12:29:28+00:00", "published_display": "15 May 2026 12:29", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA hold puts Aardvark Prader-Willi drug in limbo", "summary": "", "url": "https://finance.yahoo.com/m/4ae94c68-6536-3188-8a3e-62a42055b0af/fda-hold-puts-aardvark.html", "source_name": "BioPharma Dive", "published_at": "2026-05-15T11:58:00+00:00", "published_display": "15 May 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-adjusts-aardvark-therapeutics-114451883.html", "source_name": "MT Newswires", "published_at": "2026-05-15T11:44:51+00:00", "published_display": "15 May 2026 11:44", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Downgrades Aardvark Therapeutics to Underweight From Equalweight, Cuts Price Target to $3 From $7", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-downgrades-aardvark-therapeutics-102850381.html", "source_name": "MT Newswires", "published_at": "2026-05-15T10:28:50+00:00", "published_display": "15 May 2026 10:28", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG downgrades Aardvark Therapeutics stock rating on FDA hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOaVpOM0ptZVEtSzNrRFFMSDdTX2dVdFJOLTYxRTNId05uT05xSDY4YWxXcllWb2tzR1BoQnhtS3M3aFBpMENmUzNCbHo0SlRqY3VZMHNhLVF6cjNrMWNHa21OZ2hlWktvbkt4TmVLekdWRC1tR0kwTmhONFdTdkJaUU9TLUhaMmo2eHRYYm1jcWZFdGpNMHd5bGpyblAtMURMWmZRVDNyZDBkMW9rYV9FWFpncFFhUnc1ZEFXMWxPVQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Stock Crashes 34% \u2013 Here\u2019s Why This Analyst Finds It \u2018Hard To Lean Into\u2019 Aardvark At This Stage", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxObmY4M0JiU19lMDhiN3RtNDAzSFhsRDQ2UDYwMUt5WDZqSDJzOW4xeF9lS2h6WXlUZ0F0b0k4Mkd0a29XSzJjeTRXeElDZDVrYkJoMmE3WkF6N0otcjV0MTNKakhmMlpZUV9XWkhENnJ0WHp5UHNGTkNnX290eWFzaTlXQ1RuSy0wOHl5VzFwUkdRZDRvdDRwemhYSGFYQ2hETkpqNVUxdVJRVk1uOWxyeURR?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $19.3, Implies 187% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxPZVVWMktTVFdrVE1nams1TUdkQ1J0NWVhazdVYXBVeVJ6ZjBEUHJ2N20yMm1LeUJGTmtDbTh1NVl5WU9NT3FySUpWZG1feGRVVHFaajJzWWxqM3FvaEowTEM2WWVZcUJFTERuUkE0WXBTSkQ5b2o3TGFHbzdoS2lrU241bTd1d0otbDJjTmNoRGh5dEk1QlpJSkJlTFI4NlJxR1VhWlFCSzFPUXRycm50T3duNTdJdjE1NERGSV9LT3k3MkNaa1M3Z1NyLVlZTTFZdHllOW11Tms3ZlJNRUw0?oc=5", "source_name": "TradingView", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxNa1JtZ09uOExjWm03czFJcEM1eFpjWC1YcGVqVGdyX3hlbXNWckg0ejNlWUNyWHh1T3BGVTh6UGVmSWk1UktNVWRhWmVNQWFCejN0WjFiUGdYaEFkRFNiaUNyV0hiRnBqRGZvMGFKODJMU3hDZm9iNjcxakE1SndnT0FtZ2RDLTM4M2NxZm1nR3pGTVVzbGtQSGx4V0g5VzFhNDIwZ2Q1RmxtYVFYMUhNRVJYS2l4SHJfRmkwZ1RUbVVCZXFGMms5NVRNN2YzdEE1cGNNVENnSzN1T3kwTXUteng0VTZBQ2NZSkFlVHhRSEQ5R2s?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AARD Stock Price and Chart \u2014 NASDAQ:AARD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ZdmNseUxOWjZ1NnFkSUxwbWlkODByaVFuZXMzYk1zSk1sZzdzN0pYUk1HYjdWcXA5R2tQQ08zRkd0QlVWNmQtX1VLM29qbGpnOFZqZG1VQVJRcDB0?oc=5", "source_name": "TradingView", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$AARD stock is down 14% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOWnItRXJBV3BieV9IVHJWbTBCcmJjS3g2bjJFSTl4V0FZTEpyQnF3VG91XzZEZTlzNUhvSURTR2paZ3NKVVo3ei1JMmtPRW5ZUUtWXzF1MFUwQTRzNkU4VklHS3RSYmx5ODlNMEYybklPVXVDa05OMU1fNHVZRlJud2luTGUteFBGVVI4ZUlXLVd2Vm5SX2ZleFlibjVKdkd5ZjlN?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOVDRQeFhKNlVwUVRVNExGbzROdTg1NmZJbUVPaWZrSzN4endNNjVPNmVxYl9kckluaGY2eFBBSWFUb2FDZTYxVXZsMTRJTHRpMlpnZUN0RXppRTZYTVZKOGlKcVZ0Yk9pdUZRS3NJRkY4SnU4WmVHNlNwb2tRMjJnZDgtd3Z3YUE?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPWmdETGg5S2JNZFhWMDltaDBnR1lfaTVmdVZKYzVkUzdVaEhMMzdNQXExR3pfdmM4TmNRQmx6akp5aFI2RlpYN1NfcV9fZ3J1Qm5NZzdZdHc5ekpSSE00cXF0ZEJrZmtUc0U0cjZHQjhPQVBadVVEOVc5QkNHbHU5VGpMTDBPLTMxQ0hQbDdFX1BjcUJRbUEtVWJuNkN2RGc1RXpPNGNoQ2UyUHc4TzdRd2dIY25uektjVUJWRWQtVGpWdFhTNjRjZEdGWk1jMm5lMnFJNWxsOEpOM2pTS1lCUFFQR1hZRnBlOHJZMlhKejFMSkRQdWl6cXMwYw?oc=5", "source_name": "Benzinga", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aardvark Therapeutics (NASDAQ: AARD) posts new January 2026 presentation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNlMyTFQyLXFXQ2N0WjlOSndLa1lPVzd5cEN1c0Q2LURpXzFycGpHNm9pTDAtMWdGUmxSM0F0enJBMHNzbTNVY1hJZnRERjh5eTJUbURPSHBHdXdYQUxyanRNSFlsb2VtY0psNjVhUHQ3WGg3NlYzZFprOS1RNnFYLUttX3BHTmUzZUlzY0FybjJSNHVOWkNHT1NrRmp6Yk9QTW5aRm5EWmVlVWVfcmxEaXBzSXk?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 61, "sentiment_summary": {"positive": 10, "negative": 13, "neutral": 38, "score": 47, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 8.74, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 13}, "market_context": {"has_market_context": true, "latest_close": 7.6, "latest_week": "2026-07-10", "one_week_move": 33.3, "four_week_move": 94.9, "twelve_week_move": 45.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.545733, "market_dynamics_buy_signal": false, "relative_strength": -32.587951, "fair_value_gap": -22.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.2927, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+33.3% over one week, +94.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "Market source", "count": 8}, {"label": "simplywall.st", "count": 5}, {"label": "Stocktwits", "count": 4}, {"label": "Stock Titan", "count": 4}, {"label": "www.marketscreener.com", "count": 4}, {"label": "TradingKey", "count": 3}, {"label": "MT Newswires", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 4}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+33.3% over one week, +94.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News"}], "updated_at": "2026-07-16T02:16:27.903707+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}